BX, ENZ, GBAB, PWRM, LDF - CRWEPicks.com Stock Review!

Enzo Biochem, Inc. (NYSE:ENZ) reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations. Total revenues for the first quarter of fiscal 2011 increased to $25.7 million, from $25.2 million a year ago, or 2%, despite slightly lower revenues at Life Sciences resulting from a program to emphasize higher margined products, and advanced 3% sequentially.

Enzo Clinical Labs benefited from an increase in market share and a new provider contract. Gross profit margin improved 17% to $13.5 million, or 53% of revenues, compared to the fiscal 2010 fourth quarter’s $11.5 million and was a slight improvement year over year. R&D expenses were $1.8 million, 28% lower than both a year ago and in the July 2010 quarter, and SG&A declined $0.5 million to $11.0 million, as a percentage of revenues down 3% from a year ago and 1% from the prior quarter. Overall operating expenses, including R&D, SG&A, legal and provision for uncollectible accounts were $14.6 million, a decline of 4% from last year’s first quarter and 7% from the preceding July period.

The operating loss decreased 42%, to ($1.1) million from the corresponding year-ago period, while the net loss of ($1.1) million was 38% lower year over year. EBITDA, adjusted for approximately $1.1 million in both periods for depreciation and amortization, was $23,000, compared to a year ago EBITDA loss of ($959,000), an improvement of $936,000.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since Enzo Biochem’s founding in 1976, Enzo Biochem’s strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Biochem has three divisions: Life Sciences, Clinical Labs, and Therapeutics.

********

Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes Power3 is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.

Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which Power3 has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which Power3 is currently engaged in Phase II clinical trials.

********

The Blackstone Group (NYSE:BX) announced the completion of a 30% stake sale in Cobre Las Crucescopper mining project to Canada's Inmet Mining Corp. As disclosed earlier, the transaction value was approximately $480 million and additionally, LUK was released from a guarantee of $72 million debt owned by Las Cruces to an affiliate of Inmet. As per the terms of the agreement, of the total sales consideration, Leucadia received roughly $150 million in cash and 5.4 million Inmet’s shares (roughly 8% of outstanding shares) worth $330 million. The share issuance was based on Inmet's weighted average trading price on the Toronto Stock Exchange for the 10-day period which ended on November 26, 2010.

The Blackstone Group, L.P., together with its subsidiaries, provides alternative asset management and financial advisory services worldwide.

********

Guggenheim Build America Bonds (NYSE:GBAB) declared its initial monthly dividend of $0.1170 per share. This represents an annualized distribution rate of 7.89% based upon the closing market price of $17.79 on December 21, 2010 and an annualized 7.02% distribution rate based on the initial offering price of $20.00 on October 26, 2010.

Guggenheim Build America Bonds Managed Duration Trust (the “Trust”) is a diversified, closed-end management investment company. The Trust’s primary investment objective is to provide current income with a secondary objective of long-term capital appreciation.

********

Latin American Discovery Fund Inc. (NYSE:LDF) declared the dividends. The amount of net investment income to be paid by the funds is determined in accordance with federal income tax regulations. It is possible, that all or a portion of the funds’ fiscal year 2010 dividend may be a return of capital and that determination cannot yet be made. The amount of dividends paid by each fund may vary from time to time. Past amounts of dividends are no guarantee of future dividend payment amounts. The final determination of the source and tax characteristics of all distributions in 2010 will be made after the end of the year.

Latin American Discovery Fund Inc. is a closed-ended fund launched and managed by Morgan Stanley Investment Management Inc.

*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings, Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).